Neurofibromatosis Type 1 and 2

Neurofibromatosis type 1 (NF1) and type 2 (NF2) are autosomal dominant genetic syndromes characterized by predisposition to benign and malignant tumor development throughout the nervous system and other organ systems. NF1 results from mutations in the NF1 gene (chromosome 17q11.2), encoding neurofibromin, a tumor suppressor protein, while NF2 results from mutations in the NF2 gene (chromosome 22q12.2), encoding merlin/schwannomin, another tumor suppressor. NF1 has an incidence of approximately 1 in 3,000–3,500 live births and represents the most common single-gene neurologic disorder, while NF2 is significantly rarer (1 in 25,000 live births) but causes more aggressive CNS pathology. Both conditions demonstrate high penetrance but variable expressivity, necessitating lifelong surveillance. Recognition of these conditions is critical for early detection and intervention in potentially life-threatening complications, particularly malignant transformation and spinal cord compression.

The NF1 gene encodes neurofibromin, a RAS-GAP (GTPase-activating protein) that functions as a negative regulator of RAS signaling. In normal cells, neurofibromin converts active RAS-GTP to inactive RAS-GDP, thereby suppressing proliferative signals. Heterozygous NF1 mutations result in haploinsufficiency—reduced neurofibromin levels allow unopposed RAS activation. When the remaining wild-type allele undergoes somatic loss-of-function mutations (second-hit inactivation, consistent with the Knudson two-hit hypothesis), cells lose all neurofibromin function. This leads to constitutive hyperactivation of the RAS/MAPK (mitogen-activated protein kinase) and PI3K/AKT signaling pathways, driving uncontrolled proliferation. Cells within the neural crest—particularly Schwann cells, which wrap peripheral nerves, and cells of the neuroendocrine system—are especially susceptible to malignant transformation. The consequence is development of neurofibromas (benign tumors of Schwann cells and fibroblasts) and predisposition to malignant peripheral nerve sheath tumors (MPNST), optic pathway gliomas, pheochromocytomas, and other malignancies.

The NF2 gene encodes merlin (also called schwannomin), a cytoskeletal scaffolding protein belonging to the ERM (ezrin-radixin-moesin) family. Merlin acts as a contact-dependent growth inhibitor and tumor suppressor by regulating the Hippo signaling pathway and modulating receptor tyrosine kinase signaling. Unlike neurofibromin's role in RAS inhibition, merlin functions by suppressing YAP/TAZ (Yes-associated protein/transcriptional co-activator with PDZ-binding motif) transcriptional coactivators, which normally promote proliferation and cell survival. Loss of merlin function—through heterozygous mutations with subsequent somatic second-hit inactivation—results in uncontrolled YAP/TAZ activity and hyperactivation of Wnt and Notch signaling pathways. This is particularly relevant to Schwann cells in the peripheral and cranial nerves. Additionally, merlin loss impairs contact inhibition, allowing cells to proliferate despite high-density cellular conditions. The result is development of bilateral vestibular schwannomas (acoustic neuromas), meningiomas, and ependymomas, with a characteristic predilection for the eighth cranial nerve.

Both NF1 and NF2 exert effects primarily on neural crest–derived cells, explaining the predominance of nervous system tumors. In NF1, Schwann cells and melanocytes are most affected, leading to neurofibromas, café-au-lait spots, and optic nerve gliomas. In NF2, Schwann cells are the primary target, particularly those ensheathing vestibular nerves. The timing and location of second-hit mutations in individual cells determine which tumors develop and when, accounting for the variable expressivity between affected individuals.

Recent evidence indicates that both NF1 and NF2 pathophysiology involve not only cell-autonomous effects but also contributions from the tumor microenvironment. In NF1, neurofibromas contain a heterogeneous population of cells including mutant Schwann cells, unmutant fibroblasts, mast cells, and inflammatory infiltrates. Mast cell degranulation releases tryptase, which activates PAR-2 signaling on fibroblasts and promotes neurofibromatosis. This explains why some neurofibromas can grow substantially despite containing only a fraction of cells with biallelic NF1 mutations. Similarly, in NF2, immunologic factors may influence tumor growth rates.

Approximately 50% of NF1 cases result from inherited pathogenic variants; the remaining 50% represent de novo mutations. De novo mutations are often associated with more severe phenotypes and advanced paternal age. Over 3,000 different pathogenic NF1 variants have been identified, including frameshift mutations, nonsense mutations, missense mutations, deletions (ranging from single exons to large multi-exon deletions), and inversions. Large deletions (spanning >1 Mb) account for approximately 5% of NF1 cases and are associated with particularly severe phenotypes, including developmental delay, characteristic facial features, and increased malignancy risk. Specific mutation types correlate with clinical outcomes: nonsense mutations and frameshift mutations that result in protein truncation confer higher malignancy risk than missense mutations.

Similar to NF1, approximately 50% of NF2 cases are inherited and 50% are de novo. NF2 mutations are more frequently nonsense mutations and frameshift mutations compared to NF1. Large deletions are less common in NF2 than in NF1. Mosaic NF2 (segmental NF2) occurs when an NF2 mutation is acquired during early development and is present in some but not all cells; such individuals have a milder and often unilateral presentation.

Polymorphisms in genes involved in RAS/MAPK signaling (NF1-specific) and Hippo pathway regulation (NF2-specific) may modulate disease severity. Additionally, variants in genes controlling mismatch repair and other DNA maintenance pathways may influence mutation burden and malignancy risk.

While NF1 and NF2 are fundamentally genetic, environmental insults—particularly ionizing radiation—significantly increase the risk of secondary malignancies in affected individuals. Patients with NF1 exposed to radiation (whether therapeutic or accidental) have dramatically elevated risks of MPNST and other malignancies. This is particularly relevant in the context of cancer survivors with NF1 treated with radiation therapy.

These are the hallmark cutaneous manifestation of NF1, present in >99% of affected adults. Café-au-lait macules are tan-to-brown, flat, sharply demarcated patches typically appearing in infancy or early childhood (average age of onset 6 months to 2 years). They arise from increased melanin in melanocytes without an increase in melanocyte number. The six or more spots of ≥15 mm diameter (or ≥5 mm in children <10 years) in non-sun-exposed areas constitute a major diagnostic criterion. Café-au-lait spots do not require treatment but can be cosmetically concerning; they do not transform to melanoma directly, though patients with NF1 have modestly increased melanoma risk.

Neurofibromas are benign tumors arising from cells of the peripheral nerve sheath. They typically begin to appear in late childhood or adolescence, increase in number throughout life, and can number in the hundreds or thousands. Cutaneous neurofibromas are dome-shaped, soft nodules, typically 0.5–2 cm in diameter, that may be flesh-colored, pink, or slightly pigmented; they are present in up to 100% of adults with NF1 and cause significant cosmetic burden. Subcutaneous neurofibromas (also called plexiform neurofibromas when involving nerve plexuses) lie deeper in tissues and can grow to substantial size, potentially causing disfigurement, functional impairment, or compression of adjacent structures. A subset of patients (approximately 25–30%) develop plexiform neurofibromas during childhood; these originate from a single cell with biallelic NF1 inactivation and involve an entire nerve plexus, sometimes spanning large portions of the body. Plexiform neurofibromas carry significant morbidity risk: they may cause pain, functional limitation, disfigurement, and can undergo malignant transformation to MPNST (lifetime risk approximately 8–13% for patients with plexiform neurofibromas).

Optic pathway gliomas (usually pilocytic astrocytomas) occur in 15–20% of children with NF1, detected by imaging, though only about 1% of affected children develop clinically significant visual symptoms. Most optic pathway gliomas are indolent and do not require intervention; however, progressive gliomas can cause vision loss, proptosis, or optic disc swelling. Routine ophthalmologic screening and imaging surveillance are recommended in pediatric patients.

Approximately 70% of individuals with NF1 develop some degree of skeletal abnormality, reflecting developmental dysplasia. These include: (1) long bone dysplasia and pseudarthrosis, particularly of the tibia and fibula, presenting as bowing and pathologic fractures in children; (2) scoliosis, present in 10–25% of NF1 patients, ranging from mild curves to severe kyphoscoliosis requiring surgical intervention; (3) vertebral scalloping and dysplasia; (4) short stature, occurring in approximately 20% of NF1 patients, likely related to growth hormone dysfunction; (5) dysplasia of long bones leading to anterior bowing; and (6) sphenoid wing dysplasia, which can lead to pulsatile exophthalmos.

Hypertension is common in NF1, present in 20–25% of adolescents and adults. Approximately 1–5% of NF1 patients develop pheochromocytomas (catecholamine-secreting tumors of the adrenal medulla), which present with paroxysmal hypertension, sweating, palpitations, and headache. These tumors are frequently bilateral (in up to 50% of NF1-associated cases) and may be extra-adrenal. Screening for pheochromocytoma (by plasma free metanephrines or 24-hour urinary catecholamines) should be considered in hypertensive NF1 patients or those with symptoms suggestive of catecholamine excess. Pheochromocytomas require careful perioperative management with alpha-blockade prior to surgery.

Lifetime risk of MPNST in NF1 is 8–13% (compared to <0.001% in the general population), often arising from pre-existing plexiform neurofibromas. MPNSTs typically present in adulthood (peak incidence 20–50 years) with rapid growth of a previously stable or slowly growing mass, severe pain, neurologic dysfunction, or constitutional symptoms (fever, weight loss). They are aggressive sarcomas with poor prognosis; surgical resection is the primary treatment, with multimodal therapy often required.

Increased risk extends to multiple other cancers, including: optic pathway gliomas (already discussed), brain gliomas (particularly high-grade gliomas), gastrointestinal stromal tumors (GISTs—occurring in 5–25% of NF1 patients), pheochromocytoma (discussed), breast cancer (lifetime risk approximately 50% in women), and increased overall cancer mortality. The mechanism involves both RAS pathway hyperactivation promoting malignant transformation and, in some cases, impaired DNA repair.

Approximately 45–65% of children with NF1 have learning disabilities or developmental delays. A subset (5–15%) meet criteria for ADHD. Cognitive impairment is generally mild to moderate and does not correlate with gross tumor burden. The mechanism is incompletely understood but may involve disruption of brain development and neurofibromin's role in synaptic transmission.

The hallmark of NF2 is bilateral eighth cranial nerve schwannomas (vestibular schwannomas, acoustic neuromas), which are pathognomonic for the disorder. These benign tumors typically appear in adolescence or early adulthood (median age 20–30 years). Patients present with progressive unilateral or bilateral hearing loss (initially high-frequency sensorineural hearing loss), tinnitus, and vertigo. The bilateral nature distinguishes NF2 from sporadic unilateral acoustic neuromas. As tumors grow, they can cause facial nerve (CN VII) dysfunction, trigeminal nerve (CN V) dysfunction, brainstem compression, and obstructive hydrocephalus. Schwannomas can grow unpredictably; some remain stable for years while others grow rapidly. Hearing preservation is a major goal of management; microsurgical resection and stereotactic radiosurgery are primary interventions, chosen based on tumor size, growth rate, and hearing status.

Multiple meningiomas occur in approximately 45–80% of NF2 patients, often intracranial but also spinal. Unlike sporadic meningiomas, NF2-associated meningiomas are frequently multiple and may occur at younger ages. Most are benign but can cause mass effect and neurologic dysfunction.

Schwannomas, neurofibromas, and ependymomas commonly develop along the spinal cord in NF2, potentially causing myelopathy, radiculopathy, and myelomalacia. Spinal cord compression is a major source of morbidity.

Ocular abnormalities in NF2 include epiretinal membranes (hamartomas on the retinal surface), posterior subcapsular cataracts, and retinal hamartomas. Some patients develop cutaneous manifestations similar to NF1 (including café-au-lait spots and cutaneous neurofibromas), though typically less pronounced. Importantly, NF2 patients typically lack the widespread cutaneous neurofibromatosis seen in NF1.

Mosaic or segmental forms occur when mutation is acquired early in development, affecting a tissue region or body segment. Segmental NF1 manifests with café-au-lait spots, neurofibromas, and/or other features confined to one body region. Segmental NF2 may present with unilateral vestibular schwannomas and other tumors on one side. These variants have better prognosis than generalized forms but still require surveillance.

Clinical severity in both NF1 and NF2 varies widely, even within families. Severity does not correlate perfectly with mutation type, suggesting modifying genetic factors play a role.

NF1 is diagnosed if two or more of the following criteria are met:

There is no therapy that restores neurofibromin or merlin function; management is surveillance plus targeted intervention for symptomatic lesions.